Technology area: Chemistry & Materials
1 pending office actions • 1 art units • 1 examiners • 1 of 1 (100%) have an AI response strategy ready
Vifor Fresenius Medical Care Renal Pharma Ltd. currently has 1 pending office action in the Chemistry & Materials technology area. This action is assigned to 1 distinct examiner and is located within 1 distinct art unit. This indicates a focused prosecution effort for the company's current material-related innovations. The presence of 1 distinct art unit means the company is dealing with a single set of procedural expectations for its chemistry filings.
XU, JIANGTIAN is the busiest examiner for this portfolio, managing 1 pending office action. As the sole examiner currently reviewing the company's work, Xu's specific examination patterns will be a factor in the prosecution outcome. The fact that the 1 pending office action is handled by 1 distinct examiner allows for a highly focused prosecution strategy. This streamlined environment simplifies the coordination of the company's intellectual property efforts.
Practitioners should focus on the technical details relevant to the 1 pending office action to ensure a robust response. Because the portfolio is limited to 1 distinct art unit, the company can focus its resources on the specific examination trends of that unit. The 1 distinct examiner and 1 distinct art unit allow for a direct path toward resolving the pending matter. Strategy should be informed by the specific requirements of the Chemistry & Materials field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| XU, JIANGTIAN | 1 | 64.9% | +35.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18011951 | Manufacturing Method for Polynuclear Iron Compounds Stabilized by Carbohydrates and/or Humic Acid | XU, JIANGTIAN | 28d |
| Art Unit | Apps |
|---|---|
| 1762 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18011951 | Manufacturing Method for Polynuclear Iron Compounds Stabilized by Carbohydrates and/or Humic Acid | XU, JIANGTIAN | 1762 | §103 | Non-Final OA | 28d | AI Ready | Dec 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVifor Fresenius Medical Care Renal Pharma Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jiangtian Xu has the most, with 1 of Vifor Fresenius Medical Care Renal Pharma Ltd.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
